Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.60 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | PADI4 | Q9UM07 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24812983 | 1.00 | CA1 (0.60) | CA1CA2USP30NPC1L1NAMPT | |
| SCHEMBL25741350 | 1.00 | CA1 (0.60) | CA1CA2USP30NPC1L1NAMPT | |
| SCHEMBL4703541 | 0.96 | USP30 (0.56) | CA1CA2USP30NPC1L1NAMPT | |
| SCHEMBL2610266 | 0.93 | NAMPT (0.61) | CA1CA2USP30NPC1L1NAMPT | |
| SCHEMBL7939466 | 0.93 | NAMPT (0.61) | CA1CA2USP30NPC1L1NAMPT | |
| SCHEMBL3317089 | 0.89 | CA1 (0.59) | CA1CA2USP30NPC1L1NAMPT | |
| SCHEMBL3317093 | 0.89 | CA1 (0.59) | CA1CA2USP30NPC1L1NAMPT | |
| SCHEMBL3320831 | 0.88 | CA1 (0.58) | CA1CA2USP30NPC1L1NAMPT | |
| SCHEMBL3320824 | 0.88 | CA1 (0.58) | CA1CA2USP30NPC1L1NAMPT | |
| SCHEMBL8298895 | 0.87 | NAMPT (0.54) | CA1CA2USP30NPC1L1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CEDILLA THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4284365-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022165513-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174680-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | CA1 3740/4885CA2 3554/4885USP30 1431/4885 |
| US-20230109076-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | CA1 3740/4885CA2 3554/4885USP30 1431/4885 |
| US-12065445-B2 | CDK2 inhibitors and methods of using the same | CDK2, CDK20, CDK1 | CA1 2850/4885CA2 1979/4885USP30 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.